uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

Upcoming Webcast:


Webcast Archive:

November 29, 2017

Evercore ISI Biopharma Catalyst/ Deep Dive Conference

Wednesday, November 29, 2017
3:05 p.m. EST / 21:05 CET
Click here to view webcast 
October 19, 2017

Hemophilia B Gene Therapy Program Update

Thursday, October 19, 2017
08:30 a.m. EDT/ 14:30 CET
Click here to view the recording of the webcast 

 September 6-7, 2017

Citi's 12th Annual Biotech Conference
Thursday, September 7, 2017
11:00 a.m. EDT/17:00 CET
Click here to view webcast


Upcoming Events:

November 1 - 2, 2017
Gene Therapy for Rare Disorders, London, UK

November 1 - 2, 2017
Life Science Summit by Defined Health, New York City

November 2 - 4, 2017
Huntington's disease Study Group, Denver, CO

November 8 - 10, 2017
10th Global Forum on Research and Treatment Products for Bleeding Disorders, Montreal, Canada

November 14 - 15, 2017
2017 BioMAN Summit, Boston, MA

November 29 - 30, 2017
Evercore ISI Inaugural Biopharma Catalyst/Deep Dive Conference, Boston, MA

November 30, 2017
Barclays Gene Editing & Gene Therapy Summit Conference, New York City